| Revue: | International braz j urol |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000296700 |
| ISSN: | 1677-5538 |
| Autores: | Albuquerque, Denilson C1 Miziara, Lineu J2 Saraiva, Jose F.K3 Rodrigues, Ulisses S Ribeiro, Artur B4 Wajngarten, Mauricio5 |
| Instituciones: | 1Universidade do Estado do Rio de Janeiro, Departamento de Cardiologia, Rio de Janeiro. Brasil 2Universidade Federal de Uberlandia, Departamento de Cardiologia, Uberlandia, Minas Gerais. Brasil 3Pontificia Universidade Catolica de Campinas, Departamento de Cardiologia, Campinas, Sao Paulo. Brasil 4Universidade Federal de Sao Paulo, Departamento de Nefrologia, Ribeirao Preto, Sao Paulo. Brasil 5Universidade de Sao Paulo, Instituto do Coracao, Sao Paulo. Brasil |
| Año: | 2005 |
| Periodo: | Jul-Ago |
| Volumen: | 31 |
| Número: | 4 |
| Paginación: | 342-355 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Caso clínico, analítico |
| Resumen en inglés | OBJECTIVE: To evaluate the efficacy, safety and tolerability of sildenafil among Brazilian patients with hypertension treated with combinations of anti-hypertensive drugs. MATERIALS AND METHODS: One hundred twenty hypertensive men aged 30 to 81 years old under treatment with 2 or more anti-hypertensive drugs and with erectile dysfunction (ED) lasting for at least 6 months were enrolled at 7 research centers in Brazil. Patients were randomized to receive treatment with either sildenafil or placebo taken 1 hour before sexual intercourse (initial dose of 50 mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity). During the following 8 weeks, patients were evaluated regarding vital signs, adverse events, therapeutic efficacy, satisfaction with treatment and use of concurrent medications. RESULTS: The primary evaluation of efficacy, which was based on responses to questions 3 and 4 of the International Index of Erectile Function, showed significant differences regarding treatment with sildenafil (p = 0.0002 and p < 0.0001, respectively). In the assessment of global efficacy, 87% of the patients treated with sildenafil reported improved erections, as compared with 37% of patients given placebos (p < 0.0001). The other secondary evaluations supported the results favoring sildenafil. The most frequent adverse events among patients treated with sildenafil were headaches (11.4%), vasodilation (11.4%) and dyspepsia (6.5%). There were no significant changes in blood pressure measurements in both groups. CONCLUSION: Sildenafi |
| Disciplinas: | Medicina |
| Palabras clave: | Cirugía, Terapéutica y rehabilitación, Disfunción eréctil, Sildenafil, Hipertensión arterial, Antihipertensivos, Medicamentos |
| Keyword: | Medicine, Surgery, Therapeutics and rehabilitation, Erectile dysfunction, Sildenafil, Arterial hypertension, Antihypertensive agents, Drugs |
| Texte intégral: | Texto completo (Ver HTML) |
